|
FOR US RESIDENTS ONLY
|
Helping Healthcare Professionals
Optimize Outcomes in Ph+ CML Patients
Optimize Outcomes in Ph+ CML Patients
CML Alliance
Treatment
Support Program
Building on a 5-year legacy of improvement in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Novartis Oncology introduces CML Alliance, a unique support program designed to help optimize outcomes in Ph+ CML patients.
Targeting BCR-ABL
The BCR-ABL protein is the primary cause of Philadelphia chromosome-positive (Ph+) CML disease progression."Targeted therapy" specifically designed to bind to this protein has revolutionized the treatment of CML.
Reimbursement Support for Patients
The CML Alliance is committed to helping make Ph+ CML medications available to more patients who meet financial eligibility requirements.
Testing services offered through CML Alliance™ partners
Use of this website is governed by the
Terms of Use
and
Privacy Statement
.
Copyright 2009 Novartis Pharmaceuticals Corporation. All Rights Reserved.
|